N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: results from the EPIC cohort.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

An association between N-acetyltransferase 2 (NAT2) slow acetylation and bladder cancer has been consistently observed in epidemiologic studies. However, evidence has been mainly derived from case-control studies and was sparse from cohort studies. We evaluated the association between NAT2 slow acetylation and bladder cancer in a case-control study nested in the European Prospective Investigation into Cancer and Nutrition.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancer Epidemiol. Biomarkers Prev.

Title: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

ISSN (Electronic): 1538-7755

ISSN (Print): 1055-9965

Publication date (Electronic): Nov 2013

Volume: 22

Issue: 11

Affiliations

[1 ] Authors' Affiliations: Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Institute of the Ruhr University, Bochum; German Research Center for Environmental Health, Neuherberg; German Cancer Research Center (DKFZ), Heidelberg; Department of Epidemiology, German Institute of Human Nutrition (DIfE), Potsdam-Rehbrücke, Nuthetal; Department of Urology, University Hospital Charité, Berlin, Germany; The National Institute for Public Health and the Environment, Bilthoven; Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, the Netherlands; Danish Cancer Society Research Centre, Danish Cancer Society, Copenhagen; Department of Public Health, Institute of Epidemiology and Social Medicine, Aarhus, Denmark; INSERM, Centre for Research in Epidemiology and Population Health, Gustave Roussy Institute, Villejuif; Genetic Epidemiology Group; Nutritional Epidemiology Group, International Agency for Research on Cancer (IARC/WHO), Lyon, France;Harvard School of Public Health, Boston, Massachusetts; Academy of Athens; Hellenic Health Foundation, Greece; Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence; Epidemiology and Prevention Unit, National Cancer Institute (IRCCS), Milano; Cancer Registry and Histopathology Unit, "Civile - M.P. Arezzo" Hospital, ASP Ragusa; Department of Clinical and Experimental Medicine, Federico II University, Medical School, Naples; HuGeF Foundation, Torino, Italy; Public Health and Health Planning Directorate, Asturias; Department of Epidemiology, Catalan Institute of Oncology, Barcelona; Andalusian School of Public Health; Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Granada; Public Health Division of Gipuzkoa, Basque Regional Health Department, San Sebastian; Department of Epidemiology, Murcia Regional Health Authority, Murcia; Navarra Public Health Institute, Consortium for Biomedical Rese

Article

Publisher Item ID: 1055-9965.EPI-13-0119-T

DOI: 10.1158/1055-9965.EPI-13-0119-T

PubMed ID: 24092628

SO-VID: 716daa50-4212-448b-bb1e-f7ec9ef0c6e8

History

Data availability:

Comments

Comment on this article

scite_

Cited by 5

See all cited by